Key facts
- This page summarizes Daniel Char's Form 4 filing for ImmunoGen, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Nov 2022, 16:16.
Daniel Char - 30 Nov 2022 Form 4 Insider Report for ImmunoGen, Inc.
- Issuer symbol
- N/A
- Report date
- 30 Nov 2022
- Net transaction value
- +$2,076,000
- Form type
- 4
- Accepted by SEC
- 30 Nov 2022, 16:16:17 UTC
- Previous filing
- 30 Nov 2022
- Next filing
- 05 Feb 2024
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Renee Lentini, Attorney-in-Fact
SEC evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel Char filed Form 4 for ImmunoGen, Inc. on 30 Nov 2022.
Change
- Previous filing in this sequence was filed on 30 Nov 2022.
- Current net transaction value: +$2,076,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMGN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $2,076,000
- Shares
- +400,000
- Change %
- Price
- $5.19
- Shares after
- 400,000
- Date
- 30 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 400,000
- Exercise price
- $5.19
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant.